Global University Venturing

Karolinska Development has sold its remaining stake in BioArctic, which is based on research at Uppsala University and floated on Nasdaq Stockholm last year.

Johns Hopkins-backed biopharmaceutical developer Allakos has filed for a $75m initial public offering after raising more than $160m in equity funding.

Avexis, which is commercialising research from Ohio State University and Nationwide Children's Hospital, has been acquired by Novartis for $8.7bn.

UC Investment Office-backed gene expression technology developer Constellation Pharmaceuticals has filed for an $86.3m initial public offering.

Duke Management Company and Osage University Partners have invested in the genome editing technology spinout from Duke University.

The spinout will use a chemical processing machine invented at Flinders University to produce nanomaterials such as graphene and carbon nanotubes.

Irish institutions have spun out fewer businesses and awarded fewer licences, options and assignments than in previous years.

Launched in September 2017, Spin-Off Austria supports academics looking to establish spinouts and has selected the first eight projects.

IP Group and Penn Medicine have both returned to back a series A round for Carisma Therapeutics, the Pennsylvania spinout formerly known as Carma.

A total of 22 participants have each received $100,000 in funding as part of the UC Berkeley accelerator.